Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radafaxine · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Radafaxine | DRUG | - |
Inclusion Criteria: * Diagnosis of Major Depressive Disorder (MDD) * Duration of current depressive episode 12 weeks - 24 months * Patients can read and write at a level sufficient to provide a signed consent * If female, patients must be practicing an acceptable method of birth control Exclusion ...
Radafaxine was studied for the treatment of major depressive disorder, a form of depressive disorder. It is a small molecule therapeutic candidate developed by GSK plc. All three of its clinical trials enrolled adults aged 18 years and older who were diagnosed with major depressive disorder.
Radafaxine is developed by GSK plc, which trades under the ticker GSK. The company sponsored all three of the Phase 2 clinical trials of radafaxine in major depressive disorder, which together enrolled 1,278 participants across sites in the United States.
Radafaxine is in Phase 2 clinical development. All three of its trials were Phase 2 studies in major depressive disorder, and all three are now completed. There are no active trials of radafaxine currently listed, so it remains an investigational drug rather than an approved therapy.
Radafaxine has been evaluated in three completed Phase 2 trials: NCT00057239, which enrolled 546 adults; NCT00057226, which enrolled 365 adults; and NCT00057213, which enrolled 367 adults. Each was an 8 week study of adults diagnosed with major depressive disorder conducted in the United States.
The radafaxine Phase 2 program consisted of three completed 8 week trials in adults with major depressive disorder. The studies were randomized and double blind, and enrolled a combined total of 1,278 participants aged 18 years and older. Participants were not selected based on a biomarker.